Shares of ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) have earned an average rating of “Hold” from the seven brokerages that are presently covering the company, Marketbeat reports. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating to the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $12.75.
Several brokerages have recently commented on ZIOP. ValuEngine cut shares of ZIOPHARM Oncology from a “hold” rating to a “sell” rating in a research report on Friday, September 15th. HC Wainwright set a $10.00 price target on shares of ZIOPHARM Oncology and gave the company a “buy” rating in a report on Thursday, December 14th. Raymond James Financial reaffirmed a “hold” rating on shares of ZIOPHARM Oncology in a report on Monday, December 11th. Finally, Zacks Investment Research raised shares of ZIOPHARM Oncology from a “hold” rating to a “buy” rating and set a $5.25 price target on the stock in a report on Friday, November 10th.
Shares of ZIOPHARM Oncology (NASDAQ:ZIOP) opened at $4.14 on Friday. ZIOPHARM Oncology has a 12 month low of $3.90 and a 12 month high of $7.88. The firm has a market cap of $572.11, a PE ratio of -7.96 and a beta of 1.45.
ZIOPHARM Oncology (NASDAQ:ZIOP) last issued its earnings results on Monday, November 6th. The biotechnology company reported ($0.13) EPS for the quarter, meeting the consensus estimate of ($0.13). The firm had revenue of $1.60 million during the quarter, compared to analyst estimates of $1.66 million. ZIOPHARM Oncology’s quarterly revenue was up .0% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.11) earnings per share. equities research analysts expect that ZIOPHARM Oncology will post -0.54 earnings per share for the current year.
In related news, CEO Laurence James Neil Cooper bought 6,440 shares of the company’s stock in a transaction that occurred on Wednesday, November 8th. The shares were bought at an average price of $4.68 per share, for a total transaction of $30,139.20. Following the transaction, the chief executive officer now directly owns 1,083,731 shares of the company’s stock, valued at $5,071,861.08. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 10.40% of the stock is owned by insiders.
Hedge funds have recently made changes to their positions in the company. Chevy Chase Trust Holdings Inc. purchased a new stake in shares of ZIOPHARM Oncology in the third quarter valued at about $104,000. Amalgamated Bank grew its position in ZIOPHARM Oncology by 12.9% during the second quarter. Amalgamated Bank now owns 16,807 shares of the biotechnology company’s stock valued at $105,000 after buying an additional 1,924 shares during the period. BB&T Securities LLC bought a new position in ZIOPHARM Oncology during the second quarter valued at about $112,000. Oppenheimer & Co. Inc. grew its position in ZIOPHARM Oncology by 50.0% during the second quarter. Oppenheimer & Co. Inc. now owns 18,000 shares of the biotechnology company’s stock valued at $112,000 after buying an additional 6,000 shares during the period. Finally, Adell Harriman & Carpenter Inc. bought a new position in ZIOPHARM Oncology during the third quarter valued at about $141,000. Institutional investors own 40.23% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “ZIOPHARM Oncology Inc. (ZIOP) Given Consensus Rating of “Hold” by Brokerages” was first published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this report on another domain, it was copied illegally and reposted in violation of US and international copyright laws. The correct version of this report can be accessed at https://www.dispatchtribunal.com/2018/01/14/ziopharm-oncology-inc-ziop-given-consensus-rating-of-hold-by-brokerages.html.
ZIOPHARM Oncology Company Profile
ZIOPHARM Oncology, Inc is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The Company is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies to deliver cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease.
Receive News & Ratings for ZIOPHARM Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology and related companies with MarketBeat.com's FREE daily email newsletter.